CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Cerdulatinib (Primary)
- Indications Anaplastic large cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms CELTIC-1
- Sponsors Portola Pharmaceuticals
Most Recent Events
- 10 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Feb 2020 According to an Portola Pharmaceuticals Media Release, the company has decided not to initiate this trial until a partner is identified.
- 05 Nov 2019 According to an Portola Pharmaceuticals Media Release, company plans to launch a cerdulatinib registration study in peripheral T-cell lymphoma (PTCL) in early 2020 and will present updated data at the ASH meeting in December